Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness

Name: Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness
Creator: Health Canada
License: https://open.canada.ca/en/open-government-licence-canada

A safety review was carried out after Health Canada received a report from the European Medicines Agency, which linked hearing loss and deafness to the use of Prolia and Xgeva. After review of the report, Health Canada determined that there is not enough information to make such a link. The risk of hearing loss or deafness is already listed in the prescribing information for Xgeva (less common side effect for people with advanced bone cancer), but not for Prolia.

Publisher: Health Canada
Resources: 2
Catalogue metadata updated: 2024-05-08

Data overview

Formats: HTML
File languages: English, French

Official sources and licences

Government of Canada Open Data
Open Government Licence – Canada

Resources

Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness (English, HTML) HTML
Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness (French, HTML) HTML

Related open data

Health Canada